Plasmonic Biosensor Nanoparticles for Rapid Sepsis Biomarker Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing sepsis are time-consuming, have low accuracy, and struggle to distinguish between non-infectious and infectious organ dysfunction, leading to ineffective antibiotic treatment and potential antibiotic resistance.
Innovation Solution
Development of metal nanoparticles with a truncated octahedral structure and concave channels, integrated into a plasmonic biosensor, for high-sensitivity detection of sepsis biomarkers like oncostatin M and visfatin using surface-enhanced Raman scattering.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional diagnostic methods (quantification of procalcitonin and C-reactive protein, SOFA scoring, blood culture) are used, then diagnosis can be performed with existing technology, but the diagnosis is time-consuming and has low accuracy in distinguishing sepsis from non-infectious organ dysfunction
Solution Approach 1:
The patent changes the detection parameter from conventional markers (procalcitonin, C-reactive protein) to cytokine-specific antibodies that bind to sepsis-related cytokines. This parameter change enables more accurate and rapid detection of sepsis by directly targeting the inflammatory response markers, resolving the contradiction between diagnostic accuracy and time consumption.
Solution Approach 2:
The patent replaces the mechanical/biological processes of conventional methods (blood culture taking several days, manual SOFA scoring) with a plasmonic biosensor that uses optical detection. The surface-enhanced Raman scattering mechanism substitutes the time-consuming cultural methods with immediate optical signal detection, achieving both high accuracy and rapid results.
2Reliability
If antibiotic cocktails are administered for sepsis treatment, then treatment coverage is broad, but it is ineffective for non-infectious organ dysfunction and can trigger antibiotic resistance
Solution Approach 1:
The patent applies preliminary anti-action by using the plasmonic biosensor to accurately diagnose and differentiate sepsis from non-infectious organ dysfunction before antibiotic administration. This preliminary detection prevents unnecessary antibiotic use in non-infectious cases, thereby avoiding antibiotic resistance while ensuring effective treatment for true sepsis cases.
Solution Approach 2:
The patent establishes a feedback mechanism where the biosensor continuously monitors cytokine levels to guide antibiotic treatment decisions. By providing real-time feedback on the presence and severity of sepsis, the system enables precise adjustment of antibiotic therapy, improving treatment effectiveness while minimizing unnecessary antibiotic use and resistance development.
3Measurement precision
If existing SERS-based biosensor platforms are used, then nanoplasmonic detection can be performed, but the SERS spectral characteristics include background noise making discrimination difficult
Solution Approach 1:
The patent applies local quality by functionalizing specific regions of the metal nanoparticle surface with cytokine-specific antibodies. This localized functionalization creates distinct binding sites that selectively capture target cytokines, enhancing detection sensitivity while reducing background noise. The spatially differentiated antibody distribution on the nanoparticle surface enables precise signal discrimination without increasing overall device complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The biosensor provides precise and sensitive detection of sepsis biomarkers, enabling accurate differentiation between types of organ dysfunction and determining sepsis severity, supporting tailored treatment strategies.
Implementation Method 1
surface-enhanced Raman scattering (SERS)-based nanoplasmonic biosensors using metal nanoparticles are attracting attention as a technology for detecting small amounts of biomarkers. SERS refers to the amplification of Raman scattering between the gaps of noble metal nanoparticles or nanostructures such as gold or silver, and this is controlled by the unique optical properties of the metal nanoparticles due to the localized surface plasmon resonance (LSPR) phenomenon.
Data Source
AI summary
The present invention relates to metal nanoparticles and a plasmonic biosensor including the same. According to the present invention, it is possible to provide novel metal nanoparticles having significantly improved sensitivity to light, and further, it is possible to provide a plasmonic biosensor capable of detecting a trace amount of a biomarker present in a biological sample with high precision through the metal nanoparticles. In addition, the plasmonic biosensor is capable of detecting a sepsis biomarker with high sensitivity and specificity, and thus may be usefully used in various clinical applications such as sepsis diagnosis, identification of the type of organ dysfunction, prediction of sepsis severity, and post-treatment.